Overview

Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
An AGE-rich diet can induce after 2-6 weeks persistent increases in mediators linked to vascular dysfunction (e.g. TNFα, VCAM-1) in people with type 2 diabetes mellitus (T2DM). Benfotiamine (BT), the liposoluble derivative of vitamin B1, blocks several pathways common to hyperglycaemia- and AGE-induced endothelial dysfunction. We have shown that advanced glycation end products (AGE) of a regular mixed meal can acutely induce vascular dysfunction in T2DM and that this effects can be prevented by a three days pretreatment with BT. The hypotheses of this study are that chronical treatment with benfotiamine (900 mg/day for 6 weeks) in people with type 2 diabetes mellitus: 1. prevents postprandial impairment of endothelial function after a high-AGE meal. 2. Improves fasting endothelial function. 3. Improves parameters of autonomic function in fasting and postprandial state. 4. Improves insulin sensitivity and prevents postprandial increase in insulin resistance.
Phase:
Phase 4
Details
Lead Sponsor:
Ruhr University of Bochum
Treatments:
Benphothiamine